Clinical trials: Rifampin
HIV-1-infection, Tuberculosis
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
This is a pharmacokinetic study investigating the effect of rifampicin on the pharmacokinetics of intracellular tenofovir-diphosphate and plasma tenofovir when coadministered with tenofovir alafenamide fumarate during the…
- Trial name
- EpiTAF (NCT04424264)
- Testing
- Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid, Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid, Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz
- Where
- 2 sites in South Africa
- Volunteers
- 18 people
- Sponsor
- Professor Francois Venter
Latent Tuberculosis
2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.
Rationale: Shorter regimens of high dose daily rifampin may be safe, and as effective as the standard rifampin regimen when taken for 4 months to treat latent TB (LTBI).
- Trial name
- 2R2 (NCT03988933)
- Testing
- Rifampin double dose, Rifampin triple dose, Rifampin standard dose
- Where
- 9 sites in Canada, Indonesia and 1 more
- Volunteers
- 1,368 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Tuberculosis, Pulmonary
Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients
The 4-month daily regimen containing moxifloxacin (2HRZEM 7 / 2HRM7) of ICMR-NIRT was studied in 321 sputum positive pulmonary TB patients in a randomised clinical trial.
- Trial name
- NCT05047055
- Testing
- Isoniazid, Rifampicin, Pyrazinamide
- Where
- India
- Volunteers
- 550 people
- Sponsor
- Tuberculosis Research Centre, India
HIV
Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid
The purpose of the study is to measure the drug levels in the blood of HIV-infected individuals taking anti- HIV medication efavirenz 400 mg once daily in the presence of anti-TB medication rifampicin and isoniazid.
- Trial name
- NCT02832778
- Testing
- Efavirenz, tenofovir /emtricitabine, tenofovir/lamivudine
- Where
- 2 sites in Uganda, United Kingdom
- Volunteers
- 35 people
- Sponsor
- St Stephens Aids Trust
Healthy
Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI
Evaluation and validation of metabolic markers for the assessment of CYP3A activity and prediction of drug-drug interaction in Korean healthy subjects.
- Trial name
- CYP3A_weak (NCT02328443)
- Testing
- Midazolam, itraconazole, rifampicin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Nontuberculous Mycobacterial Infections
Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex
Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin.
- Trial name
- NCT03164291
- Testing
- Rifabutin
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- The University of Texas Health Science Center at Tyler
Sarcoidosis
Trial of Antimycobacterial Therapy in Sarcoidosis
Growing research from independent laboratories provide an association between mycobacteria and sarcoidosis. More recent immunologic and molecular studies demonstrate immune responses to mycobacteria virulence factors.
- Trial name
- CLEAR (NCT01074554)
- Testing
- Antibiotic Regimen
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt University
Solid Tumours
Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the effect of rifampicin on the PK parameters of olaparib in patients; Part B will allow patients continued access to olaparib after the PK…
- Trial name
- NCT01929603
- Testing
- Pharmacokinetic sampling, Rifampicin, Olaparib tablet dosing
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Tuberculosis, Pulmonary
Performance of Xpert MTB/RIF and XDR Assay for Diagnosis of Pulmonary Tuberculosis and Resistant Pulmonary TB
To determine how accurate Xpert MTB/RIF and XDR for diagnosis of pulmonary TB and Rifampicin resistance
- Trial name
- NCT06392594
- Testing
- xpert MTB , XDR assay
- Volunteers
- 46 people
- Sponsor
- Assiut University
Tuberculosis
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
According to WHO, about 40% of the incident TB cases in 2020 are either under-reported or under-diagnosed causing on one hand major health risks and on the other hand catastrophic financial consequences.
- Trial name
- NCT05526885
- Testing
- CAD4TB, POC-CRP, Xpert MTB/RIF Ultra
- Where
- 2 sites in Lesotho, South Africa
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Klaus Reither
NSCLC
A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711
This is a phase I study to assess the effect of itraconazole and rifampicin on the pharmacokinetic parameters of BPI-7711 in Chinese healthy volunteers.
- Trial name
- NCT04135833
- Testing
- BPI-7711, Itraconazole, Rifampicin
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Beta Pharma, Inc.
Pulmonary Tuberculosis
Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers
This trial aims to determine whether the early bactericidal activity of rifampicin given with faropenem or cefadroxil (each given with amoxicillin/clavulanic acid) is greater than the activity of rifampicin alone in patients with…
- Trial name
- NCT02381470
- Testing
- Faropenem, Amoxicillin/clavulanic acid, Cefadroxil
- Where
- 6 sites in Philippines, Singapore and 1 more
- Volunteers
- 58 people
- Sponsor
- National University Hospital, Singapore
Neoplasm Metastases
A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
The purpose of this study is to evaluate the potential effects of rifampin on blood levels of trabectedin after administration to patients with advanced malignancies.
- Trial name
- NCT01273480
- Testing
- Sequence 1, Sequence 2
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
HIV Infections, Tuberculosis
Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis
The investigators propose to conduct a phase 2 randomised (1:1) double-blind placebo-controlled trial of the dolutegravir-lamivudine-tenofovir fixed dose combination tablet daily with an additional 50 mg dose of…
- Trial name
- RADIANT-TB (NCT03851588)
- Testing
- Dolutegravir 50 mg
- Where
- South Africa
- Volunteers
- 108 people
- Sponsor
- University of Cape Town
Healthy Volunteers
A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults
This is a bioequivalence trial to evaluate the bioequivalence of Myrin P Forte against reference drug in healthy volunteers.
- Trial name
- NCT01399788
- Testing
- Myrin P Forte, Single drug references
- Where
- Singapore
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pfizer
Prostate Cancer
A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects
The study was designed to evaluate the pharmacokinetic effects of Rifampicin on HRS-5041 after oral administration of HRS-5041 tablets in healthy subjects.
- Trial name
- NCT07014488
- Testing
- HRS-5041 Tablets, Rifampicin Capsule
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
NASH - Nonalcoholic Steatohepatitis
Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
This is a non-randomized, 2-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of concomitant administration of itraconazole or rifampin on the pharmacokinetics and safety of EDP-305 in healthy human…
- Trial name
- NCT03213145
- Testing
- intraconazole, Rifampin, EDP 305
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Mild Cognitive Impairment, Dementia, Mild
Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment
The goal of this clinical trial is to compare a precision medicine approach to the standard-of-care for people with mild cognitive impairment or early-stage dementia.
- Trial name
- EVANTHEA (NCT05894954)
- Testing
- Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alzheimer's Prevention and Reversal Project, Inc.
HIV Infections
Evaluation of Three Regimens of Chemoprophylaxis for Tuberculosis in Patients co-Infected by HIV and Mycobacterium Tuberculosis
To evaluate adherence and safety of three regimens of chemoprophylaxis for tuberculosis (TB) in HIV-infected patients with positive tuberculin skin test.
- Trial name
- NCT00402454
- Testing
- isoniazid, rifampin + isoniazid or rifampin + pyrazinamide
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Sociedad Andaluza de Enfermedades Infecciosas
Rifampicin-Resistant Tuberculosis
A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis
This is a phase 3, open-label, randomized clinical trial in adults and adolescents aged 15 years or older who need treatment for rifampicin-resistant tuberculosis in South Africa.
- Trial name
- MDR-ENDPlus (NCT07675954)
- Testing
- MDR-END Plus regimen, Standard-of-care (SoC) treatment
- Where
- 2 sites in South Africa
- Volunteers
- 294 people
- Sponsor
- Seoul National University Hospital